ViiV Healthcare

{{Short description|Pharmaceutical company}}

{{hatnote|Viiv and ViiV redirect here. For other uses, see Viiv (disambiguation).}}

{{Advert|date=June 2023}}

{{EngvarB|date=September 2013}}

{{Use dmy dates|date=July 2024}}

{{Infobox company

| name = ViiV Healthcare

| logo = File:ViiV Healthcare logo 2023.png

| logo_size = 100px

| type = Joint venture

| genre =

| foundation = {{start date and age|2009}}

| founder =

| location = London, England, UK

| area_served = Worldwide

| key_people = Deborah Waterhouse (CEO)

| industry = Pharmaceutical industry

| products = Pharmaceuticals

| services =

| revenue =

| operating_income =

| net_income =

| assets =

| equity =

| num_employees = {{circa|1,100}}

| num_employees_year = 2023

| owners = {{unbulleted list|GSK plc (76.5%)|Pfizer (13.5%)|Shionogi (10%)}}

| divisions =

| subsid =

| slogan =

| homepage = {{URL|viivhealthcare.com}}

| footnotes =

| intl =

}}

ViiV Healthcare ({{IPAc-en|ˈ|v|iː|v}} {{respell|VEEV|}}) is a British multinational pharmaceutical company specializing in the research and development of medicines to treat and prevent HIV/AIDS. Its global headquarters is located in London. The company was created as a joint venture by GSK and Pfizer in November 2009, with both companies transferring their HIV assets to the new company.Jacks, Andrew [http://www.ft.com/cms/s/0/5327ff12-2aaa-11de-8415-00144feabdc0.html "GSK and Pfizer to Merge HIV Portfolios] Financial Times. 16 April 2010 {{subscription required}} In 2012, Shionogi joined the company. As of December 2023, 76.5% of the company is owned by GSK, 13.5% by Pfizer and 10% by Shionogi.{{cite web|url=http://www.viivhealthcare.com/media/press-releases/2012/october/shionogi-and-viiv-healthcare-announce-new-agreement-to-commercialise-and-develop-integrase-inhibitor-portfolio.aspx | title = Shionogi and ViiV Healthcare Announce New Agreement to Commercialise and Develop Integrase Inhibitor Portfolio | publisher = viivhealthcare.com | access-date = 7 March 2014}} According to The Financial Times, the company's co-ownership structure may change depending on the achievement of certain milestones.

ViiV Healthcare's products have a market share of approximately 32% of the global HIV therapy market, making it the second-largest healthcare company in the sector, after Gilead Sciences.{{Cite web |title=ViiV vows joint venture will help fight HIV |url=https://www.ft.com/content/d4af5df8-c8ae-11de-8f9d-00144feabdc0 |access-date=2023-11-03 |website=Financial Times|location=London}}

ViiV Healthcare's global headquarters are in London in the United Kingdom, and the company has sites in a number of other countries including the United States, Australia, Belgium, Canada, France, Germany, Italy, Japan, Mexico, the Netherlands, Portugal, Puerto Rico, Russia, Spain and Switzerland.[http://www.viivhealthcare.com/about-us/locations.aspx "ViiV Healthcare Company Website. About Us – Locations"] {{webarchive | url = https://web.archive.org/web/20101209232622/http://www.viivhealthcare.com/about-us/locations.aspx | date = 9 December 2010}} Accessed 13 October 2010